A nanoadjuvant that dynamically coordinates innate immune stimuli activation enhances cancer immunotherapy and reduces immune cell exhaustion
Source abstract
Abstract
Although conventional innate immune stimuli contribute to immune activation, they induce exhausted immune cells, resulting in suboptimal cancer immunotherapy. Here we suggest a kinetically activating nanoadjuvant (K-nanoadjuvant) that can dynamically integrate two waves of innate immune stimuli, resulting in effective antitumour immunity without immune cell exhaustion. The combinatorial code of K-nanoadjuvant is optimized in terms of the order, duration and time window between spatiotemporally activating Toll-like receptor 7/8 agonist and other Toll-like receptor agonists. K-nanoadjuvant induces effector/non-exhausted dendritic cells that programme the magnitude and persistence of interleukin-12 secretion, generate effector/non-exhausted CD8+ T cells, and activate natural killer cells. Treatment with K-nanoadjuvant as a monotherapy or in combination therapy with anti-PD-L1 or liposomes (doxorubicin) results in strong antitumour immunity in murine models, with minimal systemic toxicity, providing a strategy for synchronous and dynamic tailoring of innate immunity for enhanced cancer immunotherapy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Cancer Immunotherapy and Biomarkers · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (53)
Show source-provided references
1. Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60–65 (2017).10.1038/nature22079 ↗
2. Irvine, D. J., Swartz, M. A. & Szeto, G. L. Engineering synthetic vaccines using cues from natural immunity. Nat. Mater. 12, 978–990 (2013).10.1038/nmat3775 ↗
3. Green, J. J. & Elisseeff, J. H. Mimicking biological functionality with polymers for biomedical applications. Nature 540, 386–394 (2016).10.1038/nature21005 ↗
4. Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A. & Moon, J. J. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat. Mater. 16, 489–498 (2017).10.1038/nmat4822 ↗
5. Li, A. W. et al. A facile approach to enhance antigen response for personalized cancer vaccination. Nat. Mater. 17, 528–534 (2018).10.1038/s41563-018-0028-2 ↗
6. Macagno, A., Napolitani, G., Lanzavecchia, A. & Sallusto, F. Duration, combination and timing: the signal integration model of dendritic cell activation. Trends Immunol. 28, 227–233 (2007).10.1016/j.it.2007.03.008 ↗
7. Fries, C. N. et al. Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health. Nat. Nanotechnol. 16, 1–14 (2021).10.1038/s41565-020-0739-9 ↗
8. Lee, Y. et al. Hyaluronic acid–bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat. Mater. 19, 118–126 (2020).10.1038/s41563-019-0462-9 ↗
9. Nam, J. et al. Cancer nanomedicine for combination cancer immunotherapy. Nat. Rev. Mater. 4, 398–414 (2019).10.1038/s41578-019-0108-1 ↗
10. Dellacherie, M. O., Seo, B. R. & Mooney, D. J. Macroscale biomaterials strategies for local immunomodulation. Nat. Rev. Mater. 4, 379–397 (2019).10.1038/s41578-019-0106-3 ↗
11. Lee, S. N., Jin, S. M., Shin, H. S. & Lim, Y. T. Chemical strategies to enhance the therapeutic efficacy of Toll-like receptor agonist based cancer immunotherapy. Acc. Chem. Res. 53, 2081–2093 (2020).10.1021/acs.accounts.0c00337 ↗
12. Dowling, D. J. et al. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses. J. Allergy Clin. Immunol. 140, 1339–1350 (2017).10.1016/j.jaci.2016.12.985 ↗
13. Jin, S. M., Lee, S. N., Yoo, Y. J. & Lim, Y. T. Molecular and macroscopic therapeutic systems for cytokine-based cancer immunotherapy. Adv. Ther. 2100026, 1–19 (2021).
14. Liu, Y. et al. Synergistic immuno photothermal nanotherapy (SYMPHONY) for the treatment of unresectable and metastatic cancers. Sci. Rep. 7, 1–6 (2017).10.1038/s41598-016-0028-x ↗
15. Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F. & Lanzavecchia, A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6, 769–776 (2005).10.1038/ni1223 ↗
16. Kasturi, S. P. et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543–550 (2011).10.1038/nature09737 ↗
17. Weiden, J., Tel, J. & Figdor, C. G. Synthetic immune niches for cancer immunotherapy. Nat. Rev. Immunol. 18, 212–219 (2018).10.1038/nri.2017.89 ↗
18. Gall, C. M. Le, Weiden, J., Eggermont, L. J. & Figdor, C. G. Dendritic cells in cancer immunotherapy. Nat. Mater. 17, 472–477 (2018).
19. Langenkamp, A., Messi, M., Lanzavecchia, A. & Sallusto, F. Kinetics of dendritic cell activation: impact on priming of TH1,TH2 and nonpolarized T cells. Nat. Immunol. 1, 311–316 (2000).10.1038/79758 ↗
20. Schietinger, A. & Greenberg, P. D. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 35, 51–60 (2014).10.1016/j.it.2013.10.001 ↗
21. McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 37, 457–495 (2019).10.1146/annurev-immunol-041015-055318 ↗
22. Pulendran, B., S. Arunachalam, P. & O’Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454–475 (2021).10.1038/s41573-021-00163-y ↗
23. Pulendran, B. Learning immunology from the yellow fever vaccine: Innate immunity to systems vaccinology. Nat. Rev. Immunol. 9, 741–747 (2009).10.1038/nri2629 ↗
24. Lin, L. et al. Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8+ T cells from negative regulation by local IFN-γ. Cancer Immunol. Immunother. 68, 395–405 (2019).10.1007/s00262-018-2280-3 ↗
25. Zahm, C. D., Colluru, V. T., McIlwain, S. J., Ong, I. M. & McNeel, D. G. TLR stimulation during T-cell activation lowers PD-1 expression on CD8+ T cells. Cancer Immunol. Res. 6, 1364–1374 (2018).10.1158/2326-6066.CIR-18-0243 ↗
26. Schurich, A. et al. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog. 9, e1003208 (2013).10.1371/journal.ppat.1003208 ↗
27. Powell, M. D., Read, K. A., Sreekumar, B. K., Jones, D. M. & Oestreich, K. J. IL-12 signaling drives the differentiation and function of a TH1-derived TFH1-like cell population. Sci. Rep. 9, 1–12 (2019).10.1038/s41598-019-50614-1 ↗
28. Tanji, H., Ohto, U., Shibata, T., Miyake, K. & Shimizu, T. Structural reorganization of the Toll-Like receptor 8 dimer induced by agonistic ligands. Science 339, 1426–1429 (2013).10.1126/science.1229159 ↗
29. Maric, M. et al. Defective antigen processing in GILT-free mice. Science 294, 1361–1365 (2001).10.1126/science.1065500 ↗
30. Arunachalam, B., Phan, U. T., Geuze, H. J. & Cresswell, P. Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT). Proc. Natl Acad. Sci. USA 97, 745–750 (2000).10.1073/pnas.97.2.745 ↗
31. Irby, D., Du, C. & Li, F. Lipid–drug conjugate for enhancing drug delivery. Mol. Pharm. 14, 1325–1338 (2017).10.1021/acs.molpharmaceut.6b01027 ↗
32. Schudel, A., Francis, D. M. & Thomas, S. N. Material design for lymph node drug delivery. Nat. Rev. Mater. 4, 415–428 (2019).10.1038/s41578-019-0110-7 ↗
33. Deng, Z., Hu, J. & Liu, S. Disulfide-based self-immolative linkers and functional bioconjugates for biological applications. Macromol. Rapid Commun. 41, 1–14 (2020).10.1002/marc.201900531 ↗
34. Palucka, K. & Banchereau, J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 39, 38–48 (2013).10.1016/j.immuni.2013.07.004 ↗
35. Mailliard, R. B. et al. α-Type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64, 5934–5937 (2004).10.1158/0008-5472.CAN-04-1261 ↗
36. Lövgren, T. et al. Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists. Cancer Immunol. Immunother. 66, 1333–1344 (2017).10.1007/s00262-017-2029-4 ↗
37. Boullart, A. C. I. et al. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol. Immunother. 57, 1589–1597 (2008).10.1007/s00262-008-0489-2 ↗
38. Schulz, O. et al. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 13, 453–462 (2000).10.1016/S1074-7613(00)00045-5 ↗
39. Luft, T. et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets. Blood 100, 1362–1372 (2002).10.1182/blood-2001-12-0360 ↗
40. Legler, D. F., Krause, P., Scandella, E., Singer, E. & Groettrup, M. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J. Immunol. 176, 966–973 (2006).10.4049/jimmunol.176.2.966 ↗
41. Ahmadi, M., Emery, D. C. & Morgan, D. J. Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res. 68, 7520–7529 (2008).10.1158/0008-5472.CAN-08-1060 ↗
42. Gautier, G. et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 201, 1435–1446 (2005).10.1084/jem.20041964 ↗
43. Akira, S. & Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499–511 (2004).10.1038/nri1391 ↗
44. Kumar, V., Patel, S., Tcyganov, E. & Gabrilovich, D. I. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37, 208–220 (2016).10.1016/j.it.2016.01.004 ↗
45. Garris, C. S. et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12. Immunity 49, 1148–1161.e7 (2018).10.1016/j.immuni.2018.09.024 ↗
46. Briukhovetska, D. et al. Interleukins in cancer: from biology to therapy. Nat. Rev. Cancer 21, 481–499 (2021).10.1038/s41568-021-00363-z ↗
47. Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360–378 (2021).10.1038/s41568-021-00346-0 ↗
48. Bhagchandani, S., Johnson, J. A. & Irvine, D. J. Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants. Adv. Drug Deliv. Rev. 175, 113803 (2021).10.1016/j.addr.2021.05.013 ↗
49. Baharom, F. et al. Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells. Nat. Immunol. 22, 41–52 (2021).10.1038/s41590-020-00810-3 ↗
50. Lynn, G. M. et al. Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. Nat. Biotechnol. 38, 320–332 (2020).10.1038/s41587-019-0390-x ↗
51. Lynn, G. M. et al. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat. Biotechnol. 33, 1201–1210 (2015).10.1038/nbt.3371 ↗
52. Wilson, D. S. et al. Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity. Nat. Mater. 18, 175–185 (2019).10.1038/s41563-018-0256-5 ↗
53. Kieffer, M. E., Patel, A. M., Hollingsworth, S. A. & Seganish, W. M. Small molecule agonists of Toll-like receptors 7 and 8: a patent review 2014–2020. Expert Opin. Ther. Pat. 30, 825–845 (2020).10.1080/13543776.2020.1825687 ↗